Takeda Pharmaceutical Co Ltd
TAK13.440USD
+0.215+1.63%
Fechamento 10/31, 16:00（ET）Cotações atrasadas em 15 min
42.46BValor de mercado
1.28P/L TTM
Mais detalhes de Takeda Pharmaceutical Co Ltd Empresa
Takeda Pharmaceutical Co Ltd is a Japan-based company mainly engaged in the research and development, manufacture, sale and licensing of pharmaceuticals. The Company focuses on the main business areas of gastrointestinal diseases, rare diseases, plasma derivatives (immune diseases), oncology (cancer), and neuroscience (neuropsychiatric diseases). The Company focuses on three research and development areas: innovative biopharmaceuticals with the focus on gastrointestinal and inflammatory diseases, neuroscience, and oncology, plus plasma derivatives and vaccines. Most of the pharmaceuticals treat rare diseases in the focus disease areas and the plasma derivatives area. The Company operates in Japan, the United States, Europe, and China.
Informações de Takeda Pharmaceutical Co Ltd
Código da empresaTAK
Nome da EmpresaTakeda Pharmaceutical Co Ltd
Data de listagemMay 16, 1949
CEOMr. Christophe Weber
Número de funcionários47455
Tipo de títulosDepository Receipt
Fim do ano fiscalMay 16
Endereço4F
CidadeCHUO-KU
Bolsa de valoresNYSE Consolidated
PaísJapan
Código postal103-8668
Telefone81332782111
Sitehttps://www.takeda.com/
Código da empresaTAK
Data de listagemMay 16, 1949
CEOMr. Christophe Weber
Executivos da empresa Takeda Pharmaceutical Co Ltd
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Steven H. (Steve) Gillis, Ph.D.
Dr. Steven H. (Steve) Gillis, Ph.D.
Independent Director
Independent Director
8.26K
--
Ms. Kimberly A. Reed
Ms. Kimberly A. Reed
Independent Director
Independent Director
1.38K
-85.30%
Mr. Christophe Weber
Mr. Christophe Weber
President, Chief Executive Officer, Representative Director
President, Chief Executive Officer, Representative Director
--
--
Ms. Emiko Higashi
Ms. Emiko Higashi
Independent Director
Independent Director
--
--
Dr. John M. Maraganore, Ph.D.
Dr. John M. Maraganore, Ph.D.
Independent Director
Independent Director
--
--
Ms. Miki Tsusaka
Ms. Miki Tsusaka
Independent Director
Independent Director
--
--
Mr. Koji Hatsukawa
Mr. Koji Hatsukawa
Independent Director
Independent Director
--
--
Mr. Milano Furuta
Mr. Milano Furuta
Chief Financial Officer, Director
Chief Financial Officer, Director
--
--
Mr. Masami Iijima
Mr. Masami Iijima
Chairman of Board of Directors, Independent Director
Chairman of Board of Directors, Independent Director
--
--
Dr. Andrew S. Plump, Ph.D.
Dr. Andrew S. Plump, Ph.D.
President of Research & Development, Director
President of Research & Development, Director
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Steven H. (Steve) Gillis, Ph.D.
Dr. Steven H. (Steve) Gillis, Ph.D.
Independent Director
Independent Director
8.26K
--
Ms. Kimberly A. Reed
Ms. Kimberly A. Reed
Independent Director
Independent Director
1.38K
-85.30%
Mr. Christophe Weber
Mr. Christophe Weber
President, Chief Executive Officer, Representative Director
President, Chief Executive Officer, Representative Director
--
--
Ms. Emiko Higashi
Ms. Emiko Higashi
Independent Director
Independent Director
--
--
Dr. John M. Maraganore, Ph.D.
Dr. John M. Maraganore, Ph.D.
Independent Director
Independent Director
--
--
Ms. Miki Tsusaka
Ms. Miki Tsusaka
Independent Director
Independent Director
--
--
Detalhamento da receita
Moeda: USDAtualizado em: seg, 6 de out
Moeda: USDAtualizado em: seg, 6 de out
FY2026Q1
FY2025
FY2025Q4
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2021
FY2020
FY2019
Por EmpresaUSD
Nome
Receita
Proporção
Gastrointestinal diseases
339.30B
30.66%
Plasma derivatives
260.90B
23.57%
Rare diseases
196.40B
17.75%
Oncology
138.80B
12.54%
Neuroscience
108.60B
9.81%
Outro
62.70B
5.67%
Por RegiãoUSD
Nome
Receita
Proporção
United States
546.70B
49.40%
Europe And Canada (Country)
262.30B
23.70%
Japan
108.00B
9.76%
Latin America
57.60B
5.20%
China (Country)
43.20B
3.90%
Outro
88.90B
8.03%
Por Empresa
Por Região
Por EmpresaUSD
Nome
Receita
Proporção
Gastrointestinal diseases
339.30B
30.66%
Plasma derivatives
260.90B
23.57%
Rare diseases
196.40B
17.75%
Oncology
138.80B
12.54%
Neuroscience
108.60B
9.81%
Outro
62.70B
5.67%
Distribuição de ações
Atualizado em: sáb, 16 de ago
Atualizado em: sáb, 16 de ago
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
Capital Research Global Investors
0.42%
Parametric Portfolio Associates LLC
0.19%
Fidelity Management & Research Company LLC
0.13%
UBS Financial Services, Inc.
0.13%
Brandes Investment Partners, L.P.
0.12%
Outro
99.02%
Investidores
Investidores
Proporção
Capital Research Global Investors
0.42%
Parametric Portfolio Associates LLC
0.19%
Fidelity Management & Research Company LLC
0.13%
UBS Financial Services, Inc.
0.13%
Brandes Investment Partners, L.P.
0.12%
Outro
99.02%
Tipos de investidores
Investidores
Proporção
Investment Advisor
1.75%
Hedge Fund
0.35%
Investment Advisor/Hedge Fund
0.24%
Research Firm
0.15%
Family Office
0.01%
Family Office
0.01%
Family Office
0.01%
Outro
97.47%
Participação acionária institucional
Atualizado em: qua, 1 de out
Atualizado em: qua, 1 de out
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q3
606
78.91M
2.50%
-1.55M
2025Q2
594
72.78M
2.30%
-6.62M
2025Q1
603
72.05M
2.31%
-7.59M
2024Q4
595
73.56M
2.33%
-9.88M
2024Q3
583
77.60M
2.45%
-3.33M
2024Q2
581
73.43M
2.34%
-14.54M
2024Q1
593
78.98M
2.52%
-11.62M
2023Q4
609
83.80M
2.67%
-18.91M
2023Q3
621
81.24M
2.59%
-37.59M
2023Q2
617
84.64M
2.72%
-34.14M
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
Capital Research Global Investors
13.30M
0.42%
+94.57K
+0.72%
Jun 30, 2025
Parametric Portfolio Associates LLC
5.97M
0.19%
+676.71K
+12.78%
Jun 30, 2025
Fidelity Management & Research Company LLC
4.08M
0.13%
+275.19K
+7.23%
Jun 30, 2025
UBS Financial Services, Inc.
3.98M
0.13%
+2.28M
+133.74%
Jun 30, 2025
Brandes Investment Partners, L.P.
3.71M
0.12%
+208.14K
+5.94%
Jun 30, 2025
Renaissance Technologies LLC
3.30M
0.1%
+141.50K
+4.48%
Jun 30, 2025
Aperio Group, LLC
3.20M
0.1%
+574.34K
+21.83%
Jun 30, 2025
Millennium Management LLC
3.09M
0.1%
+2.84M
+1152.21%
Jun 30, 2025
Goldman Sachs Asset Management, L.P.
2.85M
0.09%
-44.41K
-1.53%
Jun 30, 2025
First Trust Advisors L.P.
2.60M
0.08%
-154.15K
-5.59%
Jun 30, 2025
Ver Mais
ETFs Relacionados
Atualizado em: há 10 horas
Atualizado em: há 10 horas
Nome
Proporção
VanEck Pharmaceutical ETF
2.27%
SGI Enhanced Global Income ETF
0.96%
Adasina Social Justice All Cap Global ETF
0.53%
First Trust Value Line Dividend Index Fund
0.39%
ActivePassive International Equity ETF
0.34%
Avantis International Equity ETF
0.06%
Avantis Responsible International Equity ETF
0.06%
Roundhill GLP-1 & Weight Loss ETF
0%
DFA Dimensional International Core Equity 2 ETF
0%
Invesco Zacks Multi-Asset Income ETF
0%
Ver Mais
VanEck Pharmaceutical ETF
Proporção2.27%
SGI Enhanced Global Income ETF
Proporção0.96%
Adasina Social Justice All Cap Global ETF
Proporção0.53%
First Trust Value Line Dividend Index Fund
Proporção0.39%
ActivePassive International Equity ETF
Proporção0.34%
Avantis International Equity ETF
Proporção0.06%
Avantis Responsible International Equity ETF
Proporção0.06%
Roundhill GLP-1 & Weight Loss ETF
Proporção0%
DFA Dimensional International Core Equity 2 ETF
Proporção0%
Invesco Zacks Multi-Asset Income ETF
Proporção0%
Dividendo
Um total de
1.44T
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sep 12, 2024
TAK.NB Final Cash Dividend of gross USD 0.326079 paid on Dec 12, 2024 going ex on Sep 30, 2024
Sep 30, 2024
Dec 12, 2024
Sep 30, 2024
Mar 14, 2024
TAK.NB Interim Cash Dividend of gross USD 0.292214 paid on Jul 08, 2024 going ex on Mar 27, 2024
Mar 28, 2024
Jul 08, 2024
Mar 27, 2024
Desdobramento de ações
Data
Tipo
Proporção
Sem dados
Data
Tipo
Proporção
Sem dados
